Drug Details
General Information of the Drug (ID: DR8320) | ||||
---|---|---|---|---|
Name |
Mitoxantrone
|
|||
Synonyms |
DHAD; DHAQ; Dihydroxyanthraquinone; MIX; Misostol; Mitoxanthrone; Mitoxantron; Mitoxantrona; Mitoxantronum; Mitozantrone; DHAQ HCl; Mitoxantrone [INN]; Mitozantrone hydrochloride; Mitoxantrone 2HCl; Liposome Encapsulated Mitoxantrone (LEM); Misostol (TN); Mitoxantrona [INN-Spanish]; Mitoxantrone (INN); Mitoxantrone (free base); Mitoxantronum [INN-Latin]; Novantrone (TN); AN-584/42007670; Novantrone(R) (mitoxantrone for injection concentrate); DHAQ (*Diacetate salt*); MITOXANTRONE, Mitoxantrone Hydrochloride, Mitoxantrone dihydrochloride, MITOXANTHRONE HYDROCHLORIDE; MITOXANTRONE, 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)ANTHRA-9,10-QUINONE; 1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone; 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONE; 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione; 1,4-Dihydroxy-5,8-bis(5-hydroxy-3-azapentylamino)anthrachinon; 1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione; 1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthra-9,10-quinone; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracene-9,10-dione; 5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone; 9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-(9CI)
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Approved | [1] | |
Structure |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
C22H28N4O6
|
|||
PubChem CID | ||||
Canonical SMILES |
C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO
|
|||
InChI |
1S/C22H28N4O6/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32/h1-4,23-30H,5-12H2
|
|||
InChIKey |
KKZJGLLVHKMTCM-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 65271-80-9
|
|||
ChEBI ID | ||||
GDSC | ||||
TTD Drug ID | ||||
DrugBank ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Silibinin | Carduus marianus | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | DU145 | CVCL_0105 | Prostate carcinoma | Homo sapiens | ||
LNCaP | CVCL_0395 | Prostate carcinoma | Homo sapiens | |||
PC-3 | CVCL_0035 | Prostate carcinoma | Homo sapiens | |||
Experimental
Result(s) |
The combination of silibinin and mitoxantrone exhibits a pattern of synergy in reducing cell viability with increased apoptosis. | |||||
β. A List of Natural Product(s) Able to Decrease the Adverse Effect of This Drug | ||||||
Reserpine | Rauvolfia serpentina | Click to Show/Hide the Molecular Data of This NP | ||||
Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | CD80 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | HLA-DRB5 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | KLRK1 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | YAC-1 | CVCL_2244 | Mouse lymphoma | Mus musculus | ||
B16-F10 | CVCL_0159 | Mouse melanoma | Mus musculus | |||
In-vivo Model | For a xenograft model, Female C57BL/6 mice, 6-8 weeks of age, 18-20 g, were subcutaneously (s.c.) immunized in the abdominal region with 2x105, 5x105 or 1x106 B16F10 cells. | |||||
Experimental
Result(s) |
The B16F10 tumor cell vaccine treated with MIP in combination with RP and VP was safe and efficient. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | DNA topoisomerase II (TOP2) | Molecule Info | [4] |